Form 4: UTHR CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock on October 1 and 2, 2025, under a 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving common stock.
• On October 1, 2025, 4,000 shares were acquired through stock option exercise at $120.26 per share.
• On October 1, 2025, a total of 4,000 shares were disposed of in multiple trades at weighted average prices of $423.3225, $426.0155, and $426.7773.
• On October 2, 2025, another 4,000 shares were acquired through stock option exercise at $120.26 per share.
• On October 2, 2025, a total of 4,000 shares were disposed of in multiple trades at weighted average prices of $433.0625 and $436.7.
• All reported exercises and sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, the reporting person directly holds 130 shares of common stock.
• Indirect beneficial ownership includes 166 shares by spouse and 644,193 shares across various family trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-arranged under a 10b5-1 plan, which reduces concerns about opportunistic timing. The high sale prices also reflect strong stock performance, which is positive for shareholders.

Positives

• The sale prices for the common stock were significantly higher than the exercise price of the options, indicating a substantial gain for the reporting person.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, which provides transparency and mitigates concerns about opportunistic insider trading.

Negatives

• The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is often a routine liquidity event.

Future Outlook

The pre-arranged 10b5-1 trading plan for Martine A. Rothblatt is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Management Comments

• The exercise and sale of stock options were pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.
• The 10b5-1 plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.

Industry Context

This Form 4 filing is specific to insider transactions at United Therapeutics and does not provide information on broader industry trends or competitive landscape. It reflects an individual executive's pre-planned stock transactions.

Related Party Transactions

• Shares are held indirectly by spouse and various family trusts, as detailed in the filing, which is a standard disclosure for beneficial ownership.

Stakeholder Impact

• Shareholders gain transparency regarding executive stock transactions, which were conducted under a pre-arranged plan, indicating routine financial management rather than a change in company outlook.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Next Steps

• Continuation of the pre-arranged 10b5-1 trading plan for Martine A. Rothblatt until its specified end date or exhaustion of options.

Key Dates

Recommendation

This Form 4 filing primarily reports routine, pre-arranged insider transactions and does not contain information that would fundamentally alter the investment thesis for United Therapeutics. The sales were executed under a 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings without signaling a change in company prospects. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new material information to warrant a change in investment strategy.

Keywords

UTHR, United Therapeutics, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale